This on-demand webinar shares our thoughts on evaluations for PD-1 inhibitors and assess some of the implications for manufacturers.

The points raised have broad oncology appeal as well as highlighting market access issues which have relevancy for rapidly evolving landscapes.

Discussion points:

  • Key emerging trends on market access
  • How agencies are approaching assessments for melanoma, lung cancer and RCC
  • Specific review of PD-1 testing in health technology assessments
  • Explore the move in the treatment towards combination therapies


  1. David Sykes – Founding Partner
  2. Clare Jones – Director

Click here for additional information and registration details.

Related Content

Evidence Matters 2022

Evidence Matters 2022

Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.